As Europe’s medical cannabis markets grow increasingly interconnected, Prohibition Partners has launched a first-of-its-kind digital knowledge hub to offer real-time insight into production, consumption and cross-border flows.
Today, Prohibition Partners marks the 10th edition of its flagship European Cannabis Report with a complete reimagining of how its tried and trusted cannabis intelligence is delivered.
Its new dynamic, continuously updated Insights Hub, designed to reflect the rapid pace and complexity of cannabis policy, commerce and patient access across Europe, has been designed to match the rapidly evolving regulatory landscape in real time.
The new platform, available now at insightshub.prohibitionpartners.com, moves away from static, point-in-time reports and introduces an interactive, always-on experience, offering live tracking of regulatory changes, domestic production, patient access, and critically, import and export flows.
“Since 2017, we’ve been charting the evolution of cannabis markets across Europe,” said Prohibition Partners CEO Stephen Murphy. “We knew it was time for something new that matched the pace, scale and complexity of what’s happening on the ground.”
While Europe’s medical cannabis landscape remains fragmented, with each market retaining its idiosyncrasies and unique opportunities, no country operates in isolation. Every European market with a functioning medical cannabis programme engages in some form of cross-border trade, either importing, exporting, or both.
In the below map, which provides a glimpse into Prohibition Partners’ new comprehensive knowledge platform, the varying rate of progress across the continent becomes clear.
As detailed by Prohibition Partners, Germany continues to be the largest importer in Europe, bringing in 71.5 tonnes in 2024 alone. It also plays an important role as a re-exporter, processing and distributing cannabis products to neighbours like Poland (4.8 tonnes) and the UK (approx. 2 tonnes), even though none of the cannabis is grown domestically.
The bulk of Germany’s imports originate from Canada (33 tonnes), Portugal, and Denmark, with import volumes surging more than fourfold in Q1 2025 alone following major regulatory reform under the CanG Act.
Meanwhile, Portugal has emerged as Europe’s export powerhouse, shipping 32.5 tonnes in 2024, around half of which went to Germany. Other key destinations included the UK, Spain, and Australia.
Portugal’s own import figures are not publicly disclosed, but the country plays a significant role in processing and re-exporting cannabis originally sourced from countries like Uruguay, South Africa, and Canada.
Denmark ranks as the continent’s second-largest exporter, with 10 tonnes exported in 2024, primarily to Germany and Australia. Despite its strong export credentials, Denmark still relies on imported medical cannabis, particularly flower from the Netherlands and extracts from Canada and New Zealand, for domestic patient access.
Spain’s role is unique: it has a relatively large cultivation footprint and re-exports significant volumes, despite having no formal domestic patient access framework. The country exported 7 tonnes in 2024, mostly to the UK and Germany, while importing around 4 tonnes, nearly all of which came from Portugal.
The UK, now the second-largest European medical cannabis market by volume, imported 15.5 tonnes in 2024.
While domestic cultivation is beginning to come online, the market remains heavily reliant on imports from Spain, Canada, Portugal, and Australia. Much of this supply has passed through multiple jurisdictions, highlighting the complexity and opacity of European supply chains.
In Poland, which imported 7.8 tonnes in 2024, all medical cannabis is brought in from abroad, largely from Germany. A sharp rise in demand in 2024 was linked to the growth of telemedicine platforms, although this is now being curtailed by government restrictions.
Other countries, like North Macedonia, have positioned themselves purely as exporters. In 2024, it shipped around 4 tonnes, primarily to Germany and the UK. Despite legalising medical cannabis, no domestic patients are currently treated with cannabis in North Macedonia, and all production is for export.
Similarly, the Netherlands continues to export around 4 tonnes per year, primarily through Bedrocan, with the government managing all external supply contracts. Exports are sent mostly to Germany and Italy, while domestic use remains relatively low.
As this increasingly interconnected web of cannabis supply grows more complex, the Prohibition Partners Insights Hub will allow users to explore these flows as they evolve.
Through live visualisations, country-by-country breakdowns, and dynamic mapping of trade volumes, users will be able to monitor where cannabis is being produced, processed, and consumed and how that’s shifting month-to-month.
The new platform will also cover:
With Germany’s second-phase adult-use pilot programme in limbo, the Netherlands preparing for Europe’s largest adult-use trial in April, and Switzerland drafting national legalisation legislation, 2025 is set to be a defining year for European cannabis.
The Insights Hub ensures stakeholders are not just watching history unfold, but making sense of it in real time.
The post Prohibition Partners Unveils Next-Gen Platform for Tracking European Cannabis Trends appeared first on Business of Cannabis.
Continue reading...
Today, Prohibition Partners marks the 10th edition of its flagship European Cannabis Report with a complete reimagining of how its tried and trusted cannabis intelligence is delivered.
Its new dynamic, continuously updated Insights Hub, designed to reflect the rapid pace and complexity of cannabis policy, commerce and patient access across Europe, has been designed to match the rapidly evolving regulatory landscape in real time.
The new platform, available now at insightshub.prohibitionpartners.com, moves away from static, point-in-time reports and introduces an interactive, always-on experience, offering live tracking of regulatory changes, domestic production, patient access, and critically, import and export flows.
“Since 2017, we’ve been charting the evolution of cannabis markets across Europe,” said Prohibition Partners CEO Stephen Murphy. “We knew it was time for something new that matched the pace, scale and complexity of what’s happening on the ground.”
A Growing Web of Cross-Border Supply
While Europe’s medical cannabis landscape remains fragmented, with each market retaining its idiosyncrasies and unique opportunities, no country operates in isolation. Every European market with a functioning medical cannabis programme engages in some form of cross-border trade, either importing, exporting, or both.
In the below map, which provides a glimpse into Prohibition Partners’ new comprehensive knowledge platform, the varying rate of progress across the continent becomes clear.
As detailed by Prohibition Partners, Germany continues to be the largest importer in Europe, bringing in 71.5 tonnes in 2024 alone. It also plays an important role as a re-exporter, processing and distributing cannabis products to neighbours like Poland (4.8 tonnes) and the UK (approx. 2 tonnes), even though none of the cannabis is grown domestically.
The bulk of Germany’s imports originate from Canada (33 tonnes), Portugal, and Denmark, with import volumes surging more than fourfold in Q1 2025 alone following major regulatory reform under the CanG Act.
Meanwhile, Portugal has emerged as Europe’s export powerhouse, shipping 32.5 tonnes in 2024, around half of which went to Germany. Other key destinations included the UK, Spain, and Australia.
Portugal’s own import figures are not publicly disclosed, but the country plays a significant role in processing and re-exporting cannabis originally sourced from countries like Uruguay, South Africa, and Canada.
Denmark ranks as the continent’s second-largest exporter, with 10 tonnes exported in 2024, primarily to Germany and Australia. Despite its strong export credentials, Denmark still relies on imported medical cannabis, particularly flower from the Netherlands and extracts from Canada and New Zealand, for domestic patient access.
Spain’s role is unique: it has a relatively large cultivation footprint and re-exports significant volumes, despite having no formal domestic patient access framework. The country exported 7 tonnes in 2024, mostly to the UK and Germany, while importing around 4 tonnes, nearly all of which came from Portugal.
Markets Dependent on Imports
The UK, now the second-largest European medical cannabis market by volume, imported 15.5 tonnes in 2024.
While domestic cultivation is beginning to come online, the market remains heavily reliant on imports from Spain, Canada, Portugal, and Australia. Much of this supply has passed through multiple jurisdictions, highlighting the complexity and opacity of European supply chains.
In Poland, which imported 7.8 tonnes in 2024, all medical cannabis is brought in from abroad, largely from Germany. A sharp rise in demand in 2024 was linked to the growth of telemedicine platforms, although this is now being curtailed by government restrictions.
Export-Only Markets
Other countries, like North Macedonia, have positioned themselves purely as exporters. In 2024, it shipped around 4 tonnes, primarily to Germany and the UK. Despite legalising medical cannabis, no domestic patients are currently treated with cannabis in North Macedonia, and all production is for export.
Similarly, the Netherlands continues to export around 4 tonnes per year, primarily through Bedrocan, with the government managing all external supply contracts. Exports are sent mostly to Germany and Italy, while domestic use remains relatively low.
Tracking It All In Real Time
As this increasingly interconnected web of cannabis supply grows more complex, the Prohibition Partners Insights Hub will allow users to explore these flows as they evolve.
Through live visualisations, country-by-country breakdowns, and dynamic mapping of trade volumes, users will be able to monitor where cannabis is being produced, processed, and consumed and how that’s shifting month-to-month.
The new platform will also cover:
- Regulatory changes across 30+ European markets
- Market sizing and patient access data
- Domestic cultivation and licensing frameworks
- Pricing trends and clinical adoption rates
With Germany’s second-phase adult-use pilot programme in limbo, the Netherlands preparing for Europe’s largest adult-use trial in April, and Switzerland drafting national legalisation legislation, 2025 is set to be a defining year for European cannabis.
The Insights Hub ensures stakeholders are not just watching history unfold, but making sense of it in real time.
The post Prohibition Partners Unveils Next-Gen Platform for Tracking European Cannabis Trends appeared first on Business of Cannabis.
Continue reading...
